Linezolid (n=7) | Moxifloxacin (n=15) | |
Study population | ||
Male | 6 (86%) | 11 (73%) |
Age years | 44 (37–55) | 34 (25–55) |
Bodyweight kg | 67.1 (60.5–68.4) | 67.1 (57.5–70.5) |
Creatinine concentration µmol·L−1 | 73 (72–90) | (72 (63–90) |
Dose mg·kg−1 | 8.85 (7.42–9.93) | 5.96 (5.68–7.08) |
Serum/plasma PK# | ||
Cmax mg·L−1 | 12.45 (8.84–15.78) | 2.28 (1.62–2.80) |
Tmax h | 3 (2–4) | 2 (1–2) |
AUC0–24 mg·h·L−1 | 119.4 (116.2–128.2) | 21.3 (15.8–31.0) |
Saliva PK | ||
Cmax mg·L−1 | 7.93 (7.55–12.38) | 3.20 (2.51–4.25) |
Tmax (h) | 3 (2–3) | 2 (1–2) |
AUC0–24 mg·h·L−1 | 93.6 (91.7–108.0) | 21.3 (13.7–28.3) |
Saliva to serum/plasma ratio# | ||
Paired concentration ratio | 0.76 (0.64–0.85) | 1.00 (0.68–1.35) |
AUC0–24 ratio | 0.81 (0.74–0.88) | 0.89 (0.61–1.14) |
All parameters are presented as median (interquartile range), unless stated otherwise.
#: serum for linezolid and plasma for moxifloxacin.